IRIS Accounts Production v24.2.0.383 03928993 Board of Directors 1.4.23 31.3.24 31.3.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh039289932023-03-31039289932024-03-31039289932023-04-012024-03-31039289932022-03-31039289932022-04-012023-03-31039289932023-03-3103928993ns15:EnglandWales2023-04-012024-03-3103928993ns14:PoundSterling2023-04-012024-03-3103928993ns10:Director12023-04-012024-03-3103928993ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3103928993ns10:SmallEntities2023-04-012024-03-3103928993ns10:AuditExemptWithAccountantsReport2023-04-012024-03-3103928993ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3103928993ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3103928993ns10:FullAccounts2023-04-012024-03-310392899312023-04-012024-03-3103928993ns10:Director22023-04-012024-03-3103928993ns10:Director32023-04-012024-03-3103928993ns10:Director42023-04-012024-03-3103928993ns10:RegisteredOffice2023-04-012024-03-3103928993ns5:CurrentFinancialInstruments2024-03-3103928993ns5:CurrentFinancialInstruments2023-03-3103928993ns5:Non-currentFinancialInstruments2024-03-3103928993ns5:Non-currentFinancialInstruments2023-03-3103928993ns5:ShareCapital2024-03-3103928993ns5:ShareCapital2023-03-3103928993ns5:NetGoodwill2023-03-3103928993ns5:NetGoodwill2024-03-3103928993ns5:NetGoodwill2023-03-3103928993ns5:LandBuildings2023-03-3103928993ns5:PlantMachinery2023-03-3103928993ns5:FurnitureFittings2023-03-3103928993ns5:ComputerEquipment2023-03-3103928993ns5:LandBuildings2023-04-012024-03-3103928993ns5:PlantMachinery2023-04-012024-03-3103928993ns5:FurnitureFittings2023-04-012024-03-3103928993ns5:ComputerEquipment2023-04-012024-03-3103928993ns5:LandBuildings2024-03-3103928993ns5:PlantMachinery2024-03-3103928993ns5:FurnitureFittings2024-03-3103928993ns5:ComputerEquipment2024-03-3103928993ns5:LandBuildings2023-03-3103928993ns5:PlantMachinery2023-03-3103928993ns5:FurnitureFittings2023-03-3103928993ns5:ComputerEquipment2023-03-3103928993ns5:LeasedAssetsHeldAsLessee2023-04-012024-03-3103928993ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3103928993ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3103928993ns5:RetainedEarningsAccumulatedLosses2023-03-3103928993ns5:RetainedEarningsAccumulatedLosses2023-04-012024-03-3103928993ns5:RetainedEarningsAccumulatedLosses2024-03-31
REGISTERED NUMBER: 03928993 (England and Wales)











HENDERSON BIOMEDICAL LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024






HENDERSON BIOMEDICAL LIMITED (REGISTERED NUMBER: 03928993)






CONTENTS OF THE FINANCIAL STATEMENTS
for the year ended 31 March 2024




Page

Company information 1

Balance sheet 2

Notes to the financial statements 4

Chartered accountants' report 8

HENDERSON BIOMEDICAL LIMITED

COMPANY INFORMATION
for the year ended 31 March 2024







DIRECTORS: Mrs J G Henderson
Mrs N Henderson
A F Henderson
Ms O Henderson





REGISTERED OFFICE: Unit 3
Swan Close
Croydon
Surrey
CR0 2DZ





REGISTERED NUMBER: 03928993 (England and Wales)





ACCOUNTANTS: Berringers LLP
Chartered Accountants
Lygon House
50 London Road
Bromley
Kent
BR1 3RA

HENDERSON BIOMEDICAL LIMITED (REGISTERED NUMBER: 03928993)

BALANCE SHEET
31 March 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 40,980 997,304
40,980 997,304

CURRENT ASSETS
Stocks 188,741 106,647
Debtors 6 466,989 286,735
Cash at bank and in hand 594,905 30,693
1,250,635 424,075
CREDITORS
Amounts falling due within one year 7 180,080 191,318
NET CURRENT ASSETS 1,070,555 232,757
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,111,535

1,230,061

CREDITORS
Amounts falling due after more than one year 8 705,352 885,843
NET ASSETS 406,183 344,218

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 9 406,083 344,118
SHAREHOLDERS' FUNDS 406,183 344,218

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

HENDERSON BIOMEDICAL LIMITED (REGISTERED NUMBER: 03928993)

BALANCE SHEET - continued
31 March 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 2 October 2024 and were signed on its behalf by:





Mrs J G Henderson - Director


HENDERSON BIOMEDICAL LIMITED (REGISTERED NUMBER: 03928993)

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2024

1. STATUTORY INFORMATION

Henderson Biomedical Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Tools and Equipment-25% RB
Fixtures and Fittings-25% RB
Computer Equipment-25% RB

No depreciation has been provided in respect of the freehold property due to the fact it was revalued during the period and in previous years was maintained to a standard that precludes the need for depreciation.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

HENDERSON BIOMEDICAL LIMITED (REGISTERED NUMBER: 03928993)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 March 2024

2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 16 (2023 - 14 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 April 2023
and 31 March 2024 15,250
AMORTISATION
At 1 April 2023
and 31 March 2024 15,250
NET BOOK VALUE
At 31 March 2024 -
At 31 March 2023 -

5. TANGIBLE FIXED ASSETS
Fixtures
Freehold/Investment Tools & and Computer
property Equipment fittings equipment Totals
£    £    £    £    £   
COST OR VALUATION
At 1 April 2023 980,000 37,297 5,344 62,677 1,085,318
Additions - - 36,335 999 37,334
Disposals (980,000 ) - - - (980,000 )
At 31 March 2024 - 37,297 41,679 63,676 142,652
DEPRECIATION
At 1 April 2023 - 37,039 5,237 45,738 88,014
Charge for year - 64 9,110 4,484 13,658
At 31 March 2024 - 37,103 14,347 50,222 101,672
NET BOOK VALUE
At 31 March 2024 - 194 27,332 13,454 40,980
At 31 March 2023 980,000 258 107 16,939 997,304

HENDERSON BIOMEDICAL LIMITED (REGISTERED NUMBER: 03928993)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 March 2024

5. TANGIBLE FIXED ASSETS - continued

Cost or valuation at 31 March 2024 is represented by:

Fixtures
Tools & and Computer
Equipment fittings equipment Totals
£    £    £    £   
Cost 37,297 41,679 63,676 142,652

The property was revalued by the directors during the year on an open market basis.

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 450,568 286,735
Other debtors 16,421 -
466,989 286,735

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts - 31,194
Hire purchase contracts 5,523 5,451
Trade creditors 22,520 52,787
Taxation and social security 117,746 68,075
Other creditors 34,291 33,811
180,080 191,318

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2024 2023
£    £   
Bank loans - 86,315
Hire purchase contracts - 5,523
Other creditors 705,352 794,005
705,352 885,843

Amounts falling due in more than five years:

Repayable by instalments
Bank Loan - 42,853

HENDERSON BIOMEDICAL LIMITED (REGISTERED NUMBER: 03928993)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 March 2024

9. RESERVES
Retained
earnings
£   

At 1 April 2023 344,570
Profit for the year 61,513
At 31 March 2024 406,083

CHARTERED ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS
ON THE UNAUDITED FINANCIAL STATEMENTS OF
HENDERSON BIOMEDICAL LIMITED

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance sheet. Readers are cautioned that the Income statement and certain other primary statements and the Report of the directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Henderson Biomedical Limited for the year ended 31 March 2024 which comprise the Income statement, Other comprehensive income, Balance sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of Henderson Biomedical Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Henderson Biomedical Limited and state those matters that we have agreed to state to the Board of Directors of Henderson Biomedical Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Henderson Biomedical Limited and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Henderson Biomedical Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Henderson Biomedical Limited. You consider that Henderson Biomedical Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Henderson Biomedical Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Berringers LLP
Chartered Accountants
Lygon House
50 London Road
Bromley
Kent
BR1 3RA


2 October 2024